Profile data is unavailable for this security.
About the company
Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
- Revenue in USD (TTM)0.00
- Net income in USD-15.73m
- Incorporated2001
- Employees15.00
- LocationAileron Therapeutics Inc12407 N. Mopac Expy., Suite 250 #390AUSTIN 78758United StatesUSA
- Phone+1 (617) 995-0900
- Fax+1 (617) 995-2410
- Websitehttps://aileronrx.com/
More ▼
Mergers & acquisitions
| Acquired company | ALRN:NAQ since announced | Transaction value |
|---|---|---|
| Lung Therapeutics Inc | 215.57% | 420.00k |
Data delayed at least 15 minutes, as of May 16 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDxHealth SA - ADR | 75.33m | -39.90m | 78.04m | 300.00 | -- | -- | -- | 1.04 | -1.14 | -1.14 | 0.8428 | -0.0357 | 0.5528 | 11.06 | 6.95 | 251,090.00 | -29.28 | -51.62 | -33.98 | -64.72 | 62.76 | 50.88 | -52.97 | -117.64 | 1.53 | -1.71 | 1.02 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Elutia Inc | 25.05m | -49.46m | 78.41m | 54.00 | -- | -- | -- | 3.13 | -2.35 | -2.34 | 1.24 | -2.07 | 0.5219 | 2.06 | 4.27 | 463,833.30 | -103.05 | -42.93 | -599.50 | -79.34 | 42.01 | 43.32 | -197.48 | -64.16 | 0.5499 | -1.36 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| BioXcel Therapeutics Inc | 1.76m | -153.05m | 78.44m | 74.00 | -- | -- | -- | 44.67 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Gritstone bio Inc | 15.65m | -144.89m | 81.06m | 231.00 | -- | 5.25 | -- | 5.18 | -1.57 | -1.57 | 0.17 | 0.1423 | 0.0901 | -- | 40.53 | 67,727.27 | -83.47 | -48.08 | -97.70 | -55.18 | -- | -- | -926.13 | -573.71 | -- | -554.88 | 0.7428 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Assembly Biosciences Inc | 12.95m | -51.36m | 81.16m | 65.00 | -- | 2.48 | -- | 6.27 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Aileron Therapeutics Inc | 0.00 | -15.73m | 81.40m | 15.00 | -- | 2.73 | -- | -- | -3.39 | -3.39 | 0.00 | 20.12 | 0.00 | -- | -- | 0.00 | -24.58 | -65.99 | -26.17 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 557.71k | -3.10m | 81.47m | 4.00 | -- | -- | -- | 146.08 | -0.0074 | -0.0074 | 0.0013 | -0.0181 | 0.32 | -- | 1,282.09 | 139,427.50 | -177.95 | -276.33 | -- | -- | -- | -- | -556.16 | -1,667.76 | -- | -13.22 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
| Passage Bio Inc | 0.00 | -84.44m | 82.56m | 58.00 | -- | 0.7872 | -- | -- | -1.53 | -1.53 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -47.73 | -48.56 | -52.17 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Precision BioSciences Inc | 57.53m | -19.99m | 82.97m | 109.00 | -- | 2.23 | -- | 1.44 | -5.50 | -7.41 | 13.76 | 5.38 | 0.2956 | -- | 47.10 | 527,807.30 | -10.27 | -35.35 | -12.94 | -44.22 | -- | -- | -34.74 | -147.50 | -- | -- | 0.3764 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| vTv Therapeutics Inc | 1.00m | -20.62m | 83.92m | 16.00 | -- | 4.04 | -- | 83.92 | -8.76 | -8.76 | 0.383 | 6.91 | 0.0241 | -- | 2.04 | 62,500.00 | -63.15 | -111.84 | -128.59 | -- | -- | -- | -2,621.10 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| Aclaris Therapeutics Inc | 31.12m | -77.26m | 84.09m | 91.00 | -- | 0.592 | -- | 2.70 | -1.09 | -1.09 | 0.4392 | 1.99 | 0.1541 | -- | 58.77 | 341,967.00 | -38.27 | -47.29 | -42.29 | -53.87 | 41.99 | 44.00 | -248.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Jaguar Health Inc | 9.76m | -41.30m | 84.10m | 49.00 | -- | 4.24 | -- | 8.62 | -3.64 | -3.64 | 0.4239 | 0.0676 | 0.1988 | 0.2513 | 5.08 | 199,204.10 | -85.33 | -95.29 | -153.34 | -163.54 | 79.13 | 67.28 | -429.27 | -522.28 | 1.34 | -2.95 | 0.8799 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Spero Therapeutics Inc | 103.78m | 22.81m | 84.61m | 46.00 | 3.87 | 0.7784 | 3.65 | 0.8153 | 0.4055 | 0.4055 | 1.96 | 2.02 | 0.6757 | -- | 4.01 | 2,256,087.00 | 14.85 | -35.52 | 18.36 | -41.75 | -- | -- | 21.98 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Cue Biopharma Inc | 7.02m | -49.97m | 84.64m | 53.00 | -- | 2.82 | -- | 12.06 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Sellas Life Sciences Group Inc | 0.00 | -37.34m | 84.90m | 16.00 | -- | -- | -- | -- | -1.37 | -1.37 | 0.00 | -0.2482 | 0.00 | -- | -- | 0.00 | -274.94 | -111.48 | -- | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | -- | -- | -100.00 | -- | 9.59 | -- | -- | -- |
Data as of May 16 2024. Currency figures normalised to Aileron Therapeutics Inc's reporting currency: US Dollar USD
42.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| University of Texas Investment Management Co.as of 01 May 2024 | 1.78m | 36.42% |
| Sigma Planning Corp.as of 31 Mar 2024 | 67.99k | 1.39% |
| Geode Capital Management LLCas of 31 Dec 2023 | 57.29k | 1.17% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 40.31k | 0.83% |
| Gagnon Securities LLCas of 31 Dec 2023 | 37.95k | 0.78% |
| William Blair Investment Management LLCas of 31 Mar 2024 | 28.30k | 0.58% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 28.02k | 0.57% |
| Texas Capital Bank Wealth Management Services, Inc.as of 31 Dec 2023 | 15.77k | 0.32% |
| Tower Research Capital LLCas of 31 Dec 2023 | 2.23k | 0.05% |
| UBS Securities LLCas of 31 Dec 2023 | 2.14k | 0.04% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
